Antabio SAS raises €25 m in Series B financing
Antibiotics specialist Antabio SAS has raised €25m in a Series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from existing investors.
According to Antabio SAS, the financing will be used to support the clinical development of MEM-ANT3310 to proof-of-concept.
MEM-ANT3310 is a next generation antibacterial combination designed to provide a unique coverage of priority Gram-negative pathogens including OXA-carbapenem-resistant Acinetobacter baumannii (CRAB), KPC- and OXA- carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa (PA). MEM-ANT3310 combines the well-known carbapenem meropenem (MEM) with ANT3310, a breakthrough serine-beta-lactamase (SBL) inhibitor developed by Antabio. The Class A, Class C and Class D beta-lactamase blocker is currently being tested in Phase 1 trials to treat life-threatening infections due to drug-resistant Gram-negative pathogens, including Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP).
Antimicrobial resistance (AMR) is recognised as a top priority by the World Health Organization. It is estimated that 5-10% of hospital patients in US and Europe develop a hospital-acquired (nosocomial) infection. .
Antabios portfolio includes two further programs: ANT3273, a groundbreaking, novel class, novel mode of action inhalation treatment of Pseudomonas aeruginosa (PA) infections, particularly those affecting patients with chronic pulmonary diseases (such as Bronchiectasis, Cystic Fibrosis and COPD); and ANT2681, a novel and potent metallo beta-lactamase (MBL) inhibitor to be combined with meropenem for the treatment of MBL-producing carbapenem-resistant Enterobacterales (CRE), particularly New Delhi metallo-beta-lactamase (NDM) carrying strains.
